HeartFlow Stock Surges: Analysts Raise Targets

HeartFlow's intrinsic value estimate has increased to approximately US$50.50 per share, reflecting a positive shift in analyst sentiment. Following recent Q3 results and updated guidance, multiple financial firms have elevated their price targets for the company. Stifel and Wells Fargo, for instance, raised their targets into the US$70 range, indicating stronger confidence in HeartFlow's current execution.

Canaccord and Baird also adjusted their targets upward, citing a Q3 beat and higher guidance. Piper Sandler's increased target to US$64 was supported by an analysis of HeartFlow's technology against competitors, highlighting its perceived competitive advantage in plaque analysis. Wells Fargo specifically pointed to strong trends in both FFRCT and Plaque Analysis.

Despite this bullish trend, some analysts maintain a more cautious stance. UBS initiated coverage with a Neutral rating and a US$55 target, while Morgan Stanley maintained an Equal Weight rating with a US$40 target, citing concerns about valuation and execution risk.

Looking ahead, HeartFlow anticipates significant developments, including the potential for Plaque Analysis to move to a Category 1 CPT code in 2026. This, combined with product rollouts like PCI Navigator and an expanded sales force, is expected to drive case volumes and revenue. However, execution risks such as slower adoption rates and substantial spending on sales and R&D remain points of vigilance.